(2)
Press Release
Hørsholm, Denmark (26 January 2021) - Allarity Therapeutics A/S ( Allarity or the Company ) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the British variant ), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU).
The virus variant was labelled Variant of Concern 202012/01 by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other Coronavirus variants. This variant has also been identified in the U.S. in several states.